{"id":"NCT03198728","sponsor":"Marius Pharmaceuticals","briefTitle":"Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men","officialTitle":"A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-05","primaryCompletion":"2020-05-01","completion":"2020-05-01","firstPosted":"2017-06-26","resultsPosted":"2023-06-28","lastUpdate":"2023-06-28"},"enrollment":314,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism, Male"],"interventions":[{"type":"DRUG","name":"SOV2012-F1","otherNames":[]},{"type":"DRUG","name":"AndroGel","otherNames":[]}],"arms":[{"label":"SOV2012-F1-treated","type":"EXPERIMENTAL"},{"label":"Andro-Gelâ„¢ treated","type":"ACTIVE_COMPARATOR"}],"summary":"This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month (275-day) safety evaluation period.","primaryOutcome":{"measure":"Percentage of Male Hypogonadal Subjects With Average NaF/EDTA Plasma Total Testosterone (T Cavg) Within the Normal Range Using Oral SOV2012-F1.","timeFrame":"90 days","effectByArm":[{"arm":"SOV2012-F1 Treated","deltaMin":166,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["38606384"],"seeAlso":["https://clinicaltrials.gov/ct2/show/NCT04467697"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":214},"commonTop":["Upper respiratory tract infection","Hypertension","Influenza","Viral upper respiratory tract infection","Arthralgia"]}}